NasdaqGS:AGIOBiotechs
Agios Pharmaceuticals (AGIO) Could Be 11% Undervalued Following Mixed Sickle Cell Updates
Agios Pharmaceuticals (AGIO) shares are reacting to mixed sickle cell disease updates, as the company ends development of tebapivat for this indication while securing FDA Priority Review for its mitapivat supplemental application.
See our latest analysis for Agios Pharmaceuticals.
At a share price of $36.36, Agios Pharmaceuticals has seen short term momentum cool, with a 7 day share price return down 8.21% and a 30 day share price return down 4.06%. This comes even as its 90 day share price...